Skip to Navigation
Skip to Main Content
Skip to Related Content
to view your mail
Yahoo Finance Plus
U.S. Markets closed
Citius Pharmaceuticals, Inc. (CTXR)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 4:00PM EDT
5,272 reactions on $CTXR conversation
Sign in to post a message.
Citius went up to the mid-4's in anticipation of early approval, so we KNOW that we are looking at more than a double in 5 months, and 4-5 times upon a positive phase 3 outcome in January (as expected). It will be moving up slowly as we approach December, and everyone will be wondering why they didn't load up under 2.
THE MOST OBVIOUS DOUBLE++ in the market!!
The fact that company ownership has not sold and continues to add shares to their positions is a big indicator for me. I don't understand why it isn't a bigger deal for the CTXR community!?
Correction: If Mino-Lok wasn’t proving superior efficacy in trials, why would the FDA have granted it Fast Track status?
Seems like nothing much to discuss now because we have already discussed almost everything about CTXR, its pipe line product, trials & etc.
We even include the general outlook of the economy and some fiscal policies that may affect the company.
Perhaps the time now is for the CTXR Mgt./PR to say something or anything that is "positive". We will pick that up analyze and have active discussion again. A win win situation, for the company as well for retail investors.
The outrageous approval of an ineffective Alzheimer’s drug (annual cost $57K), which precipitated the very public resignations-in-protest of three committee members, has made FDA committees paranoid. Nobody, including CTXR executives, could have seen this controversial event coming down the tracks. Because Mino-Lok has “Fast Track,” no doubt the FDA committee riding herd on it are now strongly inclined to let the Phase 3 Trial run out the clock before making any recommendation. If Mino-Lok was proving superior efficacy in trials, why would the FDA have granted it Fast Track status?
Remember when people said this was the next millionaire stock. LOL.
most of the biopharma stocks became highly attractive to investors due to NURO up almost 800% this week following their FDA designation news. CTXR and DARE next!!!!!
Why its up today? Any news?
Any chance the DMC can decide to halt the trial between now and year-end due to efficacy?
I have a question relative to Motley report today.
They said that CTRX had deasappointed results. But, I don't understand why. They continue their phase, there is no bad news, isn' it ?
dont know if u guys notice but institutions holdings keep raising .
that is pretty positive indicator.glta.
Look, red again! Shocking? No
Great article by Broad Street on CTXR today. Here is part of it:
WE are continuing our coverage of Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products.
Current price $2.23 per share
After opening at $2.13/share in Wednesday’s session CTXR shares closed out the day at $3.23 (+3.24%) after an above average trading volume of 11.7M shares.
Too many times we’ve seen biopharma stocks lose 50% or more of their value because their phase III clinicals received bad news from an FDA review or were required to make significant modifications to their advanced clinical trial.
That’s not the case with Mino-Lok, the lead product at CTXR. The company has been advised, with 65% of the trial enrollment completed, to carry on and complete the phase III trial with no modifications required or suggested. That’s a big positive for any biopharma company in advanced clinical trials.
As the company stated in a press release Tuesday; “the independent Data Monitoring Committee (DMC), following its third interim review, recommended continuing the Phase 3 trial for Mino-Lok® without modification. This recommendation affirms that there is an important efficacy signal that merits moving forward with the trial, there are no safety concerns to warrant halting the trial.”
Many biopharma companies would have seen their market value soar on news like that.
The market for Mino-Lok has been estimated at $750M in the USA and $1.8B globally. Those figures are a good indicator of what the market value of CTXR could be just based on one product.
As we said earlier, there had been a couple of posts last week that were unflattering about the prospects of CTXR based on the recent phase III interim analysis of Mino-Lok. We don’t know why those articles were posted, but we do know how to “follow the money”. The level of short interest in CTXR shares is/was 12.38% of the public float, or about 15M shares and those short sellers may have made a killing last week
My experience with this stock tells me we have hit bottom and should be a steady march from here, but who knows.
I prefer my bear meat skewered and well-done in an air fryer personally...
Shouldn't there be a class action against the law firm who first initiate a class action against CTXR. Let the 2 law firms fight and we be the audience. Just wish to see some sort of boomerang effect or say, the law will work like a double edge sword. Price drop and investors suffered economic loss. No? What about M.Fool next in turn?
With the SP dropping so much recently on no news, it is apparent that this stock has been owned by our younger holders who expect short term gratification. I want to remind people that phase 3 of the MinoLoc trial will be ending in around 6 months, and I'll bet that the SP will run up again in anticipation of approval.
A double in anticipation of the results by November/December (5 months) and probably a quadruple in January.
This is the time to BUY, not flee. If you think you can get back in BEFORE everybody else does, then you are being a little short-sighted. Now is the time to LOAD UP at these bargain prices.
Good luck to all longs!
$CTXR , Hold on every body, Earnings Date is Aug 12, 2021 - Aug 16, 2021
I see the law suit alleging that Citius execs not being honest about DMC news. My understanding is that DMC only reviews safety and may issue a directive regards futility. They do not judge standard of care superiority. Am I wrong here?
The moles (shorts:) will retreat into their holes in due time after their misguided and under-researched arguments against the merit of CTXR enterprise. Enjoy with humor their diatribe or mute and ignore. $10 or higher in forward year. Do your own due diligence.
New Jersey Governor sounds alarm on 'pandemic of the unvaccinated'
‘It’s going to be an exceptional back to school season’: USPA Global Licensing President
Yahoo Finance Video
Raw beef recall: Greater Omaha Packing recalls 295k pounds of raw beef for possible E. coli contamination
Advertise with us
© 2021 Verizon Media. All rights reserved.
About Our Ads
Discover new investment ideas by accessing unbiased, in-depth investment research